Clinical Trials Browser

Enrolling by invitation × Clear-cell metastatic renal cell carcinoma × 90 days × Clear all

NCT07488572 2026-03-23

Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study

Phase 2 Enrolling by invitation

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell